Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate*
暂无分享,去创建一个
D. Clarke | T W Loo | D M Clarke | T. Loo
[1] I. Pastan,et al. Genetic analysis of the multidrug transporter. , 1995, Annual review of genetics.
[2] P. Gros,et al. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Akabas,et al. Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment. , 1996, Biophysical journal.
[4] L. Greenberger,et al. Functional Evidence That Transmembrane 12 and the Loop between Transmembrane 11 and 12 Form Part of the Drug-binding Domain in P-glycoprotein Encoded by MDR1 (*) , 1995, The Journal of Biological Chemistry.
[5] D. Clarke,et al. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.
[6] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[7] S. Chifflet,et al. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. , 1988, Analytical biochemistry.
[8] Michael M. Gottesman,et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.
[9] M. Akabas,et al. Locating the Anion-selectivity Filter of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel , 1997, The Journal of general physiology.
[10] D. Clarke,et al. Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12* , 1997, The Journal of Biological Chemistry.
[11] M. Azzaria,et al. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance , 1989, Molecular and cellular biology.
[12] P. Gros,et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. , 1993, Biochemistry.
[13] D. Clarke,et al. Inhibition of Oxidative Cross-linking between Engineered Cysteine Residues at Positions 332 in Predicted Transmembrane Segments (TM) 6 and 975 in Predicted TM12 of Human P-glycoprotein by Drug Substrates* , 1996, The Journal of Biological Chemistry.
[14] D. Clarke,et al. Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*) , 1995, The Journal of Biological Chemistry.
[15] D. Clarke,et al. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. , 1994, The Journal of biological chemistry.
[16] I. Pastan,et al. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.
[17] D. Clarke,et al. Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.
[18] I. Pastan,et al. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. , 1994, Molecular pharmacology.
[19] L. Greenberger,et al. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. , 1993, The Journal of biological chemistry.
[20] D. Clarke,et al. Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators* , 1997, The Journal of Biological Chemistry.
[21] D. Clarke,et al. The Minimum Functional Unit of Human P-glycoprotein Appears to be a Monomer* , 1996, The Journal of Biological Chemistry.
[22] D. Clarke,et al. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.
[23] B. Sankaran,et al. P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic Site (*) , 1995, The Journal of Biological Chemistry.
[24] D. Clarke,et al. Covalent Modification of Human P-glycoprotein Mutants Containing a Single Cysteine in Either Nucleotide-binding Fold Abolishes Drug-stimulated ATPase Activity (*) , 1995, The Journal of Biological Chemistry.
[25] M. Relling,et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.